Trial Profile
A Multi-center, Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Suvorexant Versus Placebo on Sleep Pressure and Circadian Rhythm in Hypertensives With Insomnia: The Super 1 Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Acronyms Super1
- 15 Mar 2019 Primary endpoint (Reduction of sleep systolic blood pressure) has not been met.
- 15 Mar 2019 Results (n=82) published in the Journal of Clinical Hypertension (Greenwich).
- 20 Jan 2017 Status changed from not yet recruiting to recruiting.